-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bipolar disorder is named because the mood disorder has both emotional extremes or bipolar states - depression and mania.
about 4 percent of Americans have different degrees of bisople disorder.
rates are the same for men and women.
usually in their teens, 20s or 30s.
are rare in children with bispleual disorders.
pharmaceutical company Celon announced today that a Phase II study by Falkieri (heptaminate dry powder inhaler) to treat drug-resistant biphasic depression has yielded positive results.
in this trial, the total MADRS score in patients in the Falkieri group was statistically significantly lower in week 2 than in placebo, so the trial reached its main endpoint.
at a dose of 24 mg, the difference between MADRS minus placebo was -5.9 (95% CI:-10.2 to -1.5, p s 0.009) and at a dose of 36 mg, the difference between MADRS minus placebo was -6.7 (95% CI: -11.1 to -2.2, p to 0.004); at a dose of 48 mg, the difference between MADRS minus placebo is -8.2 (95% CI:-12.6 to -3.7, p .lt;0.001).
this is a multi-center study of 88 adult patients with double-blind, placebo-controlled patients who did not respond well to evidence-based treatment for at least two biplent depressions.
were assigned 24 mg, 36 mg or 48 mg Falkieri or placebo twice a week for two weeks.
